# ATTR amyloidosis with cardiomyopathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy

> No upcoming FDA catalysts in ATTR amyloidosis with cardiomyopathy; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [AMVUTTRA® (vutrisiran) topline data readout](https://sec-api.dev/pdufa/vutrisiran) | ALNY | ATTR amyloidosis with cardiomyopathy | completed, positive | "In June 2024, we reported positive topline results from the HELIOS-B clinical trial of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000026/alny-20241231.htm)) |
| 1H 2025 | [Nucresiran trial start](https://sec-api.dev/pdufa/nucresiran) | ALNY | ATTR amyloidosis with cardiomyopathy | scheduled | "We expect to initiate the TRITON-CM Phase 3 clinical trial of nucresiran in patients with ATTR amyloidosis with cardiomyopathy in the first half of 2025, and expect to initiate the TRITON-PN Phase 3 clinical trial of nucresiran in patients with hATTR polyneuropathy in late 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000052/alny-20250331.htm)) |
| March 20, 2025 | [AMVUTTRA® (vutrisiran) FDA approval](https://sec-api.dev/pdufa/vutrisiran) | ALNY | ATTR Amyloidosis with Cardiomyopathy | completed, approved | "Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1178670/000117867025000038/pressreleaseforcmapproval.htm)) |

## Drugs

- [AMVUTTRA® (vutrisiran)](https://sec-api.dev/pdufa/vutrisiran) (ALNY)
- [Nucresiran](https://sec-api.dev/pdufa/nucresiran) (ALNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ATTR amyloidosis with cardiomyopathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy

```bibtex
@misc{secapidev_indications_attr_amyloidosis_with_cardiomyopathy_20261116,
  title        = {ATTR amyloidosis with cardiomyopathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_attr_amyloidosis_with_cardiomyopathy_20261116","title":"ATTR amyloidosis with cardiomyopathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/attr-amyloidosis-with-cardiomyopathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
